Avadel Pharmaceuticals (AVDL) Downgraded by Zacks Investment Research to Sell

Avadel Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Avadel Pharmaceuticals Downgraded by Zacks Investment Research on 10/11/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of Avadel Pharmaceuticals traded up $0.18 on Monday, reaching $10.18. 949948 shares of the stock traded hands, compared to its average volume of 460482. Shares of Avadel Pharmaceuticals were trading at $10.18 on Monday. The firm’s 50 day moving average is $8.44 and its 200 day moving average is $8.00.Avadel Pharmaceuticals has a 12 month low of $9.92 and a 12 month high of $10.80. While on yearly highs and lows, Avadel Pharmaceuticals’s today has traded high as $10.50 and has touched $9.92 on the downward trend. See More Analyst Rating at: RATING

Avadel Pharmaceuticals Earnings and What to expect: 

Avadel Pharmaceuticals last issued its quarterly earnings results on August 8th, 2021. The reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.02. Avadel Pharmaceuticals has generated ($0.75) earnings per share over the last year (($0.95) diluted earnings per share). Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($1.33) to ($0.42) per share. Avadel Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 8th, 2021 based off prior year’s report dates.

Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($1.33) to ($0.42) per share. The P/E ratio of Avadel Pharmaceuticals is -10.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Avadel Pharmaceuticals is -10.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Avadel Pharmaceuticals has a P/B Ratio of 3.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Avadel Pharmaceuticals (AVDL) Moving Average Technical Analysis

5 day Moving Average is $9.94 And 5 day price change is -$0.04 (-0.39%)  with average volume for 5 day average is 581,020. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $9.16 and 20 day price change is $2.38 (30.51%) and average 20 day moving volume is 577,220. 50 day moving average is $8.44  and 50 day price change is $2.41 ( 31.02%)  and with average volume for 50 days is : 386,622. 200 day moving average is $8.00  and 200 day price change is $3.17 (45.22%)  and with average volume for 200 days is : 383,835.

Other owners latest trading in Avadel Pharmaceuticals :

  • On 8/23/2021 shares held by Morgan Stanley were 376,265 which equates to market value of $2.53M and appx 0.00% owners of Avadel Pharmaceuticals
  • On 8/17/2021 shares held by Wells Fargo & Company MN were 214,950 which equates to market value of $1.45M and appx 0.00% owners of Avadel Pharmaceuticals
  • On 8/17/2021 shares held by Woodline Partners LP were 232,537 which equates to market value of $1.57M and appx 0.00% owners of Avadel Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 56.04% for Avadel Pharmaceuticals

See More Analyst Rating at: RATING